肝癌合并肝硬化脾功能亢进患者的细胞免疫功能研究及临床意义

肝脏 ›› 2021, Vol. 26 ›› Issue (6): 632-637.

肝癌合并肝硬化脾功能亢进患者的细胞免疫功能研究及临床意义

贾哲, 张珂, 黄容海, 赫嵘, 鲁岩, 蒋力

100015 北京首都医科大学附属北京地坛医院普外科

收稿日期:2020-07-03 出版日期:2021-06-30 发布日期:2021-07-19
通讯作者: 蒋力,Email:jiangli1903@163.com
基金资助:
北京市教育委员会科技计划面上项目(KM201710025026)

The study of cellular immune function and its clinical significance in patients with liver cancer combined with liver cirrhosis and hypersplenism

JIA Zhe, ZHANG Ke, HUANG Rong-hai, HE Rong, LU Yan, JIANG Li

Department of General Surgery, Beijing Di Tan Hospital, Capital Medical University, No. 8, JingShun East Street, Chaoyang District, Beijing 100015, China

Received:2020-07-03 Online:2021-06-30 Published:2021-07-19
Contact: JIANG Li, Email:jiangli1903@163.com

摘要/Abstract

摘要： 目的肝癌合并肝硬化脾功能亢进的患者同健康人群比较,机体细胞免疫功能的改变及其对临床评估和治疗的意义。方法笔者收集了罹患肝硬化肝癌患者27名,利用流式细胞术及免疫组化技术同健康人群比较外周血及肝、脾组织内细胞免疫功能;并同时对肝硬化肝癌患者的外周血及肝脾内免疫指标行相关性分析。结果同健康人群比较,肝癌合并肝硬化脾功能亢进的患者外周血CD4⁺T淋巴细胞百分比明显下降,CD8⁺T淋巴细胞百分比明显升高,CD4⁺/CD8⁺T细胞比例明显下降,同时该类患者肝脾组织内的细胞免疫功能较正常人群亦明显下降。结论肝癌合并肝硬化脾功能亢进的患者存在显著的细胞免疫功能失调。

关键词: 肝癌, 肝硬化, 脾功能亢进, 细胞免疫功能

Abstract: Objective To investigate the difference of cellular immune function between liver cancer patients complicated with liver cirrhosis and hypersplenism and healthy people, and its significance for clinical evaluation and treatment.Methods Twenty-seven liver cancer patients complicated with liver cirrhosis were selected. The cellular immune function of peripheral blood, liver and spleen tissues detected by flow cytometry and immunohistochemistry were compared between patients and healthy cases. The correlation of the immune indexes between peripheral blood and liver and spleen tissues in patients was analyzed.Results Compared with healthy controls, in the peripheral blood of the patients, the percentage of CD4⁺ T lymphocytes and the ratio of CD4⁺ to CD8⁺ T cells were lower, and the percentage of CD8⁺ T lymphocytes was higher. Besides, the cellular immune function in the liver and spleen tissues of these patients was poorer compared with healthy population.Conclusion The cellular immune of liver cancer patients complicated with liver cirrhosis and hypersplenism is dysfunctional.

Key words: Liver cancer, Liver cirrhosis, Hypersplenism, Cell immune function

贾哲, 张珂, 黄容海, 赫嵘, 鲁岩, 蒋力. 肝癌合并肝硬化脾功能亢进患者的细胞免疫功能研究及临床意义[J]. 肝脏, 2021, 26(6): 632-637.

JIA Zhe, ZHANG Ke, HUANG Rong-hai, HE Rong, LU Yan, JIANG Li. The study of cellular immune function and its clinical significance in patients with liver cancer combined with liver cirrhosis and hypersplenism[J]. Chinese Hepatolgy, 2021, 26(6): 632-637.

参考文献

[1] Mahipal A, Tella SH, Kommalapati A, et al. Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel. Cancers (Basel), 2019, 11.
[2] Busato D, Mossenta M, Baboci L, et al. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Rev Clin Pharmacol, 2019, 12: 453-470.
[3] Eggert T, Greten TF. Tumor regulation of the tissue environment in the liver. Pharmacol Ther, 2017, 173: 47-57.
[4] Tahmasebi Birgani M, Carloni V. Tumor Microenvironment, a Paradigm in Hepatocellular Carcinoma Progression and Therapy. Int J Mol Sci, 2017, 18.
[5] Roth GS, Decaens T. Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives. Eur J Cancer, 2017, 87: 101-112.
[6] Schrader J, Iredale JP. The inflammatory microenvironment of HCC - the plot becomes complex. J Hepatol, 2011, 54: 853-855.
[7] Zhang Q, Lou Y, Bai XL, et al. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression. World J Gastroenterol, 2018, 24: 3500-3512.
[8] Hirakawa Y, Ogata T, Sasada T, et al. Immunological consequences following splenectomy in patients with liver cirrhosis. Exp Ther Med, 2019, 18: 848-856.
[9] Sakaki M, Hiroishi K, Baba T, et al. Intrahepatic status of regulatory T cells in autoimmune liver diseases and chronic viral hepatitis. Hepatol Res, 2008, 38: 354-361.
[10] Dooley S, Ten Dijke P. TGF-beta in progression of liver disease. Cell Tissue Res, 2012, 347: 245-256.
[11] Unitt E, Marshall A, Gelson W, et al. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol, 2006, 45: 246-253.
[12] Hashimoto N, Shimoda S, Kawanaka H, et al. Modulation of CD4(+) T cell responses following splenectomy in hepatitis C virus-related liver cirrhosis. Clin Exp Immunol, 2011, 165: 243-250.
[13] Sumida K, Shimoda S, Iwasaka S, et al. Characteristics of splenic CD8⁺ T cell exhaustion in patients with hepatitis C. Clin Exp Immunol, 2013, 174: 172-178.
[14] Kudo M. Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update. Oncology, 2017, 93 Suppl 1: 147-159.

[1]	于蕊, 孙倩, 师强伟, 王春峰, 姚建宁, 张连峰. 合并少肌症对肝硬化患者行经颈静脉肝内门体分流术后发生肝性脑病的影响[J]. 肝脏, 2021, 26(6): 602-605.
[2]	赵凯, 薛晋峰, 薛鹏飞, 常鹏. 阿帕替尼对中晚期肝癌患者TACE术后血管生成因子水平的影响[J]. 肝脏, 2021, 26(6): 628-631.
[3]	杨庆玺, 苏吉亮, 孙忠文, 刘元勋, 胡文娟. 21例肝癌合并脑梗死患者临床特点观察[J]. 肝脏, 2021, 26(6): 642-645.
[4]	李飞龙, 张子倩. 转移性肝癌合并肝性脑病短期内死亡风险的潜在影响因素研究[J]. 肝脏, 2021, 26(6): 646-649.
[5]	曹旭峰, 王建华, 潘涛. 超声造影与超声弹性成像对原发性肝癌和肝泡型包虫病的鉴别价值[J]. 肝脏, 2021, 26(6): 692-695.
[6]	梁书菀. 肝癌合并门静脉癌栓微创治疗的进展分析[J]. 肝脏, 2021, 26(6): 703-705.
[7]	白艳锋, 何玲玲, 魏红山. 食管胃底静脉曲张出血患者低肝脏弹性值原因分析[J]. 肝脏, 2021, 26(5): 490-493.
[8]	商连琴, 岳冬黎, 朱炳喜. 乙型肝炎肝硬化上消化道出血无创性预测模型的建立[J]. 肝脏, 2021, 26(5): 497-501.
[9]	单勤星, 张晓东, 王鑫. 能谱CT单能量成像及金属伪影削减算法在肝硬化门静脉高压TIPS术后血管成像的应用[J]. 肝脏, 2021, 26(5): 502-504.
[10]	杜居洁, 郑红, 李金. 超声内镜检查术检查乙型肝炎肝硬化患者食管侧支静脉曲张的价值分析[J]. 肝脏, 2021, 26(5): 505-509.
[11]	陆观珠, 包玉洁, 白玉盘, 焉雷, 许洁. 人乳牙牙髓干细胞治疗肝硬化小鼠模型的研究[J]. 肝脏, 2021, 26(5): 510-513.
[12]	廖新爱, 冯惠娟, 卓传尚, 叶治, 柳丽娟. 原发性肝癌患者外周血单个核细胞线粒体DNA含量检测及其临床意义[J]. 肝脏, 2021, 26(5): 514-517.
[13]	王闯胜, 孙婕, 石佳. 水隔离技术用于原发性肝癌MWA治疗对患者3年预后的影响[J]. 肝脏, 2021, 26(5): 527-529.
[14]	沈宇, 万伟, 立全晰, 吴星星. HBV相关性肝癌患者合并不同程度肝硬化对预后的影响[J]. 肝脏, 2021, 26(5): 530-533.
[15]	吉晓妹, 邵春燕, 吉浩明, 顾春燕. 人血白蛋白序贯治疗对原发性肝癌合并肝硬化患者射频消融术后肝功能和预后的影响[J]. 肝脏, 2021, 26(5): 534-537.